Monte Rosa Therapeutics, Inc. (GLUE)
9.31
-1.00
(-9.70%)
USD |
NASDAQ |
Nov 12, 16:00
9.50
+0.19
(+2.04%)
After-Hours: 20:00
Monte Rosa Therapeutics Gross Profit Margin (Quarterly) : 96.06% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 96.06% |
| June 30, 2026 | 78.69% |
| March 31, 2026 | 51.81% |
| December 31, 2025 | 24.92% |
| September 30, 2025 | 83.59% |
| June 30, 2025 | 90.84% |
| Date | Value |
|---|---|
| March 31, 2025 | 97.59% |
| December 31, 2024 | 96.60% |
| September 30, 2024 | 77.18% |
| June 30, 2024 | 56.12% |
| March 31, 2024 | -78.29% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| United Therapeutics Corp. | 88.10% |
| ACADIA Pharmaceuticals, Inc. | 89.75% |
| Alnylam Pharmaceuticals, Inc. | 75.19% |
| Anika Therapeutics, Inc. | 61.57% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -33.00% |
| Return on Assets | -21.59% |
| Return on Invested Capital | -30.08% |
| Profit Margin (Quarterly) | 5.63% |
| Operating Margin (Quarterly) | -3.57% |
| Return on Net Operating Assets | -205.2% |